Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669197 · ClinicalTrials.gov registry record · Phase 2
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
A Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma, sponsored by HonorHealth Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04669197 is a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 19 participants, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04669197, a Phase 2 study of Locally Advanced Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by HonorHealth Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Hydroxychloroquine
- DRUG Paclitaxel protein bound
Study Locations (1)
Arizona
- HonorHealth Research Institute - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04669197
The ClinicalTrials.gov registry entry for NCT04669197 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 66-participant average among 18 other Locally Advanced Pancreatic Adenocarcinoma trials with a reported enrollment target (71% lower). The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Locally Advanced Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.
NCT04669197 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT04669197 about?
NCT04669197 is a clinical study titled "Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer". To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
What is the current status of trial NCT04669197?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2020-12-01. Estimated completion is 2025-12-30.
What conditions does trial NCT04669197 study?
This clinical trial studies the following conditions: Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Untreated Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT04669197?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Hydroxychloroquine (DRUG), Paclitaxel protein bound (DRUG).
Who is sponsoring clinical trial NCT04669197?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669197 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
RECRUITING · Phase 2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
RECRUITING · Phase 1
Explore more on PlainTrial
Locally Advanced Pancreatic Adenocarcinoma
All registered trials for this condition
Borderline Resectable Pancreatic Adenocarcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.